The PE Ratio as of September 2024 (TTM) for Erasca, Inc. (ERAS) is -3.08

According to Erasca, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.08. This represents a change of 28.65% compared to the average of -2.39 of the last 4 quarters.

Erasca, Inc. (ERAS) Historical PE Ratio (quarterly & annually)

How has ERAS PE Ratio performed in the past?

The mean historical PE Ratio of Erasca, Inc. over the last ten years is -44.44. The current -3.08 PE Ratio has changed 593.01% with respect to the historical average. Over the past ten years (40 quarters), ERAS's PE Ratio was at its highest in in the December 2022 quarter at -1.04. The PE Ratio was at its lowest in in the June 2020 quarter at -18.69.

Erasca, Inc. (ERAS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Erasca, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Erasca, Inc. (ERAS) Average PE Ratio

How has ERAS PE Ratio performed in the past?

The current PE Ratio of Erasca, Inc. (ERAS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Erasca, Inc. (ERAS) PE Ratio vs. Peers

How is ERAS’s PE Ratio compared to its peers?

Erasca, Inc.’s PE Ratio is less than Century Therapeutics, Inc. (-0.91), less than NGM Biopharmaceuticals, Inc. (-0.91), greater than Keros Therapeutics, Inc. (-11.28), greater than Monte Rosa Therapeutics, Inc. (-3.11), greater than Gracell Biotechnologies Inc. (-12.26), greater than Theseus Pharmaceuticals, Inc. (-3.19), greater than Design Therapeutics, Inc. (-5.23), greater than Edgewise Therapeutics, Inc. (-14.14), greater than C4 Therapeutics, Inc. (-3.44), greater than Mineralys Therapeutics, Inc. (-4.63), greater than Cullinan Oncology, Inc. (-6.96), greater than Sana Biotechnology, Inc. (-4.82), greater than Olema Pharmaceuticals, Inc. (-6.07), less than aTyr Pharma, Inc. (-2.33), less than Zentalis Pharmaceuticals, Inc. (-1.08), less than Relay Therapeutics, Inc. (-2.57), greater than Stoke Therapeutics, Inc. (-7.92), greater than Pliant Therapeutics, Inc. (-4.19), greater than Black Diamond Therapeutics, Inc. (-3.70), greater than Arvinas, Inc. (-5.42),

Build a custom stock screener for Erasca, Inc. (ERAS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Erasca, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Erasca, Inc. (ERAS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Erasca, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.